Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024)
Clinical Drug Investigation · 2026
DOI: 10.1007/s40261-026-01552-0 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Drug Investigation, 2026. Verfasst von Marina Alacoque Rodrigues und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Universidade Federal de Minas Gerais - UFMG, Brazil, 6627 Antonio Carlos Ave, Belo Horizonte, Minas Gerais, 31270010, Brazil. Hauptthemen laut MEDLINE: Multiple Myeloma, Drug Approval, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: The value of new therapies depends on the magnitude of their clinical benefit. In multiple myeloma (MM), numerous drugs have been approved in the past two decades, yet the extent of clinical benefit at authorization remains uncertain. This study evaluated MM drugs approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA), and the Brazilian Health Regulatory Agency (Anvisa). METHODS: This retrospective cohort study assessed MM drugs approved between 2003 and 2024. Data were extracted from publicly available regulatory documents. Clinical benefits were assessed using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale for Haematological Malignancies (ESMO-MCBS:H v 1.1) based on pivotal trials. Descriptive statistics, Kaplan-Meier curves and log-rank tests were performed. RESULTS: During the study period, the EMA approved 17 drugs for MM, with 11 (64.7%) supported by single-arm studies and 4 (23.5%) through accelerated assessment. The FDA also approved 17 drugs, with 12 (70.6%) based on single-arm studies, 11 (64.7%) through expedited pathways, and 8 (47.1%) designated as Breakthrough Therapies. Anvisa approved 12 drugs, with 7 (58.3%) under priority registration. According to the ESMO-MCBS:H v1.1 scoring, only 4 of 17 drugs (23.5%) demonstrated meaningful clinical benefit, defined as a grade ≥4 in the non-curative setting. Accelerated timelines in Brazil were significantly associated with biologicals, monoclonal antibodies, and Breakthrough Therapy status (all p < .05). CONCLUSION: Most MM therapies approved entered the market with limited evidence of meaningful clinical benefit. These findings support using the ESMO-MCBS:H to guide regulatory and reimbursement decisions in resource-constrained settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Universidade Federal de Minas Gerais - UFMG, Brazil, 6627 Antonio Carlos Ave, Belo Horizonte, Minas Gerais, 31270010, Brazil.
- Fundação Ezequiel Dias - FUNED, Brazil, Belo Horizonte, Brazil.
- College of Pharmacy, Universidade Federal de Minas Gerais - UFMG, Brazil, 6627 Antonio Carlos Ave, Belo Horizonte, Minas Gerais, 31270010, Brazil. amreis@outlook.com.
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Rodrigues, M. A., de Pádua, C. A. M., de Miranda Drummond, P. L., de Souza, P. H. C., Malta, J. S., & Reis, A. M. M. (2026). Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024). Clinical Drug Investigation. https://doi.org/10.1007/s40261-026-01552-0
Vancouver
Rodrigues MA, de Pádua CAM, de Miranda Drummond PL, de Souza PHC, Malta JS, Reis AMM. Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024). Clinical Drug Investigation. 2026. doi:10.1007/s40261-026-01552-0
BibTeX
@article{Rodrigues2026,
author = {Rodrigues, Marina Alacoque and de Pádua, Cristiane Aparecida Menezes and de Miranda Drummond, Paula Lana and de Souza, Pedro Henrique Carvalho and Malta, Jéssica Soares and Reis, Adriano Max Moreira},
title = {Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024)},
journal = {Clinical Drug Investigation},
year = {2026},
doi = {10.1007/s40261-026-01552-0}
}
EUVIMED